stoxline Quote Chart Rank Option Currency Glossary
  
Bluejay Diagnostics, Inc. (BJDX)
2.26  -0.35 (-13.41%)    11-16 11:52
Open: 2.68
High: 2.68
Volume: 5,808
  
Pre. Close: 2.61
Low: 2.26
Market Cap: 3(M)
Technical analysis
2026-11-16 11:13:17 AM
Short term     
Mid term     
Targets 6-month :  3.22 1-year :  3.88
Resists First :  2.75 Second :  3.32
Pivot price 2.37
Supports First :  1.84 Second :  1.53
MAs MA(5) :  2.61 MA(20) :  2.4
MA(100) :  3.76 MA(250) :  8.44
MACD MACD :  -0.2 Signal :  -0.3
%K %D K(14,3) :  56.4 D(3) :  72.2
RSI RSI(14): 38.5
52-week High :  28 Low :  1.84
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BJDX ] has closed above bottom band by 34.2%. Bollinger Bands are 75.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 84 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.04 - 3.06 3.06 - 3.08
Low: 2.48 - 2.49 2.49 - 2.51
Close: 2.59 - 2.61 2.61 - 2.63
Company Description

Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.

Headline News

Sat, 14 Nov 2026
BJDX - Bluejay Diagnostics, Inc. | News - OTC Markets

Thu, 12 Nov 2026
Bluejay Diagnostics, Inc. (BJDX) Has Cash Through Q2 2027; FDA Filing Targeted for H1 2027 - TradingView

Wed, 11 Nov 2026
BJDX: Bluejay Diagnostics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Fri, 30 Oct 2026
Bluejay Diagnostics, Inc. (BJDX) Sets 1-for-4 Reverse Split Effective Nov. 3 - TradingView

Tue, 08 Sep 2026
BJDX Stock Draws Traders As Cash, Trial And 13G Align - StocksToTrade

Mon, 06 Jul 2026
BJDX Stock Slides As Traders Watch Support Levels - timothysykes.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 2 (%)
Held by Institutions 11 (%)
Shares Short 36 (K)
Shares Short P.Month 33 (K)
Stock Financials
EPS -14.32
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 18.98
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -51.1 %
Return on Equity (ttm) -98.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -6.47
Qtrly Earnings Growth 0 %
Operating Cash Flow -6 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -0.16
PEG Ratio 0
Price to Book value 0.11
Price to Sales 0
Price to Cash Flow -0.43
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android